Search results
Results from the WOW.Com Content Network
Rates of composite major bleeding or clinically relevant non-major bleeding were 2.7% in the placebo group, 3.2% in the ELIQUIS 2.5 mg group, and 4.3% in the ELIQUIS 5 mg group.
Apixaban is recommended by the National Institute for Health and Clinical Excellence for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation and at least one of the following risk factors: prior stroke or transient ischemic attack, age 75 years or older, diabetes, or symptomatic heart failure.
The U.S. government on Tuesday released a list of 10 prescription medicines that will be subject to the first-ever price negotiations by the Medicare health program that covers Americans aged 65 ...
AOL latest headlines, entertainment, sports, articles for business, health and world news.
The drugs include the blood thinner Eliquis, diabetes treatment Jardiance and eight other medications. The negotiation process was authorized under the Inflation Reduction Act, which Biden signed ...
Get the latest news, politics, sports, and weather updates on AOL.com.
There were also consistently lower rates of major bleeding and of intracranial bleeding with ELIQUIS compared with warfarin across all evaluated CHADS 2, CHA 2 DS 2 VASc, and HAS-BLED score ...
Lawsuits over Xarelto began piling up in 2014 and the companies had so far won all six trials over Xarelto's alleged bleeding risk. Bayer, J&J settle thousands of U.S. Xarelto lawsuits for $775 ...